Xiaoli Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoli Zhang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Jing Hao
Key Laboratory of The Ministry of Education for Experimental Teratology, Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhua Xi Road, Jinan, Shandong, PR China
9 shared publications - Jie Chai
Department of Gastrointestinal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
6 shared publications - Lanlan Liu
Key Laboratory of The Ministry of Education for Experimental Teratology, Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Shandong, China
6 shared publications - Ruihong Zhang
Key Laboratory of The Ministry of Education for Experimental Teratology, Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Shandong, China
6 shared publications - Sujuan Zhi
Key Laboratory of the Ministry of Education for Experimental Teratology, Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine Shandong University Jinan Shandong People's Republic of China
6 shared publications - Weiwei Cui
Key Laboratory of The Ministry of Education for Experimental Teratology, Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Shandong, China
6 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published byĀ IMR PressĀ inĀ British Journal of Hospital Medicine
- Vol.Ā 87 Ā (7)
Assessment of the Reporting Quality of Randomized Controlled Trials on Peer Tutoring in Medical Education
Aims/Background: Peer tutoring (PT) has been increasingly adopted as an innovative pedagogical approach in medical education. However, the methodological rigor and reporting quality of randomized controlled trials (RCTs) evaluating PT remain unclear. This study aimed to assess the reporting quality of PT-related RCTs using the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines. Methods: A systematic search of PubMed, Embase, and Web of Science was conducted to identify RCTs that investigated PT interventions among medical students, focusing on publications after 2010. Eligible studies were screened independently by two researchers. Reporting quality was evaluated using the 28-item CONSORT 2010 checklist, and overall quality scores (OQSs) were calculated. Results: Forty-eight RCTs were included. The majority were published after 2015, with 37.5% between 2016 and 2020 and 35.4% between 2021 and 2025. Most studies were conducted in Europe or North America (75%), while 25% were from Asia. Approximately 81.3% of publications included in this analysis were published in journals with an impact factor below 4. The median OQS was 20 (range: 7ā24). High compliance was observed for items such as abstract structure (95.8%), intervention details (100%), and outcome definition (100%), whereas randomization restriction (27.1%), allocation concealment (27.1%), implementation (25.0%), adverse event reporting (2.1%), and protocol availability (33.3%) were poorly reported. Conclusion: Despite the growing application of RCTs to evaluate PT in medical education, adherence to CONSORT 2010 remains suboptimal. Key methodological elementsāparticularly randomization, allocation concealment, and trial registrationāwere frequently underreported, which limits the interpretability and reproducibility of studies. Targeted training, stricter journal requirements, and education-specific CONSORT extensions are recommended to improve reporting quality in future PT-related RCTs. Registration: PROSPERO (CRD420261355464).
- 20 July 2026
- Published byĀ IMR PressĀ inĀ British Journal of Hospital Medicine
- Vol.Ā 87 Ā (7)
Open AccessAssessment of the Reporting Quality of Randomized Controlled Trials on Peer Tutoring in Medical Education
Aims/Background: Peer tutoring (PT) has been increasingly adopted as an innovative pedagogical approach in medical education. However, the methodological rigor and reporting quality of randomized controlled trials (RCTs) evaluating PT remain unclear. This study aimed to assess the reporting quality of PT-related RCTs using the Consolidated Standards of Reporting Trials (CONSORT) 2010 guidelines. Methods: A systematic search of PubMed, Embase, and Web of Science was conducted to identify RCTs that investigated PT interventions among medical students, focusing on publications after 2010. Eligible studies were screened independently by two researchers. Reporting quality was evaluated using the 28-item CONSORT 2010 checklist, and overall quality scores (OQSs) were calculated. Results: Forty-eight RCTs were included. The majority were published after 2015, with 37.5% between 2016 and 2020 and 35.4% between 2021 and 2025. Most studies were conducted in Europe or North America (75%), while 25% were from Asia. Approximately 81.3% of publications included in this analysis were published in journals with an impact factor below 4. The median OQS was 20 (range: 7ā24). High compliance was observed for items such as abstract structure (95.8%), intervention details (100%), and outcome definition (100%), whereas randomization restriction (27.1%), allocation concealment (27.1%), implementation (25.0%), adverse event reporting (2.1%), and protocol availability (33.3%) were poorly reported. Conclusion: Despite the growing application of RCTs to evaluate PT in medical education, adherence to CONSORT 2010 remains suboptimal. Key methodological elementsāparticularly randomization, allocation concealment, and trial registrationāwere frequently underreported, which limits the interpretability and reproducibility of studies. Targeted training, stricter journal requirements, and education-specific CONSORT extensions are recommended to improve reporting quality in future PT-related RCTs. Registration: PROSPERO (CRD420261355464).
- Open Access
- 27 November 2025
- Published byĀ American Association for Cancer Research (AACR)
Supplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- 27 November 2025
- Published byĀ American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- Open Access
- 27 November 2025
- Published byĀ American Association for Cancer Research (AACR)
Data from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Colon cancer stem cells (CSC) are tumor-initiating cells that drive tumorigenesis and progression through self-renewal and various differentiation potency. Therefore, the identification of factors critical for colon CSC function is vital for the development of therapies. Sohlh2 belongs to the superfamily of bhlh transcription factors and serves as a tumor suppressor in several tumors. The role of Sohlh2 in CSCs remains unknown. Here we demonstrated that Sohlh2 was related to the inhibition of LncRNA-H19/miR-141/β-catenin signaling and led to the consequent suppression of colon CSC stemness and the promotion of colon CSC differentiation in vitro and in vivo. Moreover, Sohlh2 could directly bind to the promoter of LncRNA-H19 and repress its transcription activity. LncRNA-H19 mediated the effects of Sohlh2 on colon CSC stemness and differentiation. Clinically, we observed a significant inverse correlation between Sohlh2 and LncRNA-H19, β-catenin, Lgr5, CD133 expression levels, and positive correlation between Sohlh2 and MUC2, TFF2 expression in colon cancer tissues. Collectively, our findings suggest an important role of the Sohlh2/LncRNA-H19/miR-141/β-catenin pathway in regulating colon CSC stemness and differentiation, suggesting potential therapeutic targets for colon cancer.Implications:This study identifies that Sohlh2 directly manipulates LncRNA-H19 transcription and suppresses the β-catenin signaling pathway and the Sohlh2/LncRNA-H19/miR-141/β-catenin signaling pathway plays an essential role in the stemness of colon CSCs.
- 27 November 2025
- Published byĀ American Association for Cancer Research (AACR)
Open AccessData from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Colon cancer stem cells (CSC) are tumor-initiating cells that drive tumorigenesis and progression through self-renewal and various differentiation potency. Therefore, the identification of factors critical for colon CSC function is vital for the development of therapies. Sohlh2 belongs to the superfamily of bhlh transcription factors and serves as a tumor suppressor in several tumors. The role of Sohlh2 in CSCs remains unknown. Here we demonstrated that Sohlh2 was related to the inhibition of LncRNA-H19/miR-141/β-catenin signaling and led to the consequent suppression of colon CSC stemness and the promotion of colon CSC differentiation in vitro and in vivo. Moreover, Sohlh2 could directly bind to the promoter of LncRNA-H19 and repress its transcription activity. LncRNA-H19 mediated the effects of Sohlh2 on colon CSC stemness and differentiation. Clinically, we observed a significant inverse correlation between Sohlh2 and LncRNA-H19, β-catenin, Lgr5, CD133 expression levels, and positive correlation between Sohlh2 and MUC2, TFF2 expression in colon cancer tissues. Collectively, our findings suggest an important role of the Sohlh2/LncRNA-H19/miR-141/β-catenin pathway in regulating colon CSC stemness and differentiation, suggesting potential therapeutic targets for colon cancer.Implications:This study identifies that Sohlh2 directly manipulates LncRNA-H19 transcription and suppresses the β-catenin signaling pathway and the Sohlh2/LncRNA-H19/miR-141/β-catenin signaling pathway plays an essential role in the stemness of colon CSCs.
- Open Access
- 27 March 2025
- Published byĀ MDPI AGĀ inĀ International Journal of Molecular Sciences
- Vol.Ā 26 Ā (7) , 3088
PTEN: A Novel Diabetes Nephropathy Protective Gene Related to Cellular Senescence
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The current diagnostic and therapeutic approaches need to be improved. Cellular senescence has been implicated in the pathogenesis of DN, but its precise role remains unclear. This study aimed to identify key pathogenic genes related to cellular senescence in DN and explore their potential as diagnostic biomarkers. Using transcriptomic data from GEO datasets (GSE96804, GSE30122, GSE142025, and GSE104948) and cellular senescence-related genes sourced from the GenAge database, we integrated multiple bioinformatics approaches, including differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning and proteināprotein interaction (PPI), to identify diagnostic genes. PTEN was identified as a key diagnostic gene. Immune infiltration analysis revealed that PTEN expression is positively correlated with macrophage M2 and dendritic cell resting infiltration and negatively correlated with monocytes and neutrophils. snRNA analysis revealed that PTEN is mainly expressed in mesangial cells. Finally, RT-PCR results revealed that the mRNA expression of PTEN was upregulated in kidneys from db/db mice. Additionally, high-glucose treatment significantly upregulated PTEN expression in cultured human mesangial cells. This study identifies PTEN as a potential diagnostic biomarker for DN which may contribute to early detection and personalized therapeutic strategies.
- 27 March 2025
- Published byĀ MDPI AGĀ inĀ International Journal of Molecular Sciences
- Vol.Ā 26 Ā (7) , 3088
Open AccessPTEN: A Novel Diabetes Nephropathy Protective Gene Related to Cellular Senescence
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The current diagnostic and therapeutic approaches need to be improved. Cellular senescence has been implicated in the pathogenesis of DN, but its precise role remains unclear. This study aimed to identify key pathogenic genes related to cellular senescence in DN and explore their potential as diagnostic biomarkers. Using transcriptomic data from GEO datasets (GSE96804, GSE30122, GSE142025, and GSE104948) and cellular senescence-related genes sourced from the GenAge database, we integrated multiple bioinformatics approaches, including differential expression analysis, weighted gene co-expression network analysis (WGCNA), machine learning and proteināprotein interaction (PPI), to identify diagnostic genes. PTEN was identified as a key diagnostic gene. Immune infiltration analysis revealed that PTEN expression is positively correlated with macrophage M2 and dendritic cell resting infiltration and negatively correlated with monocytes and neutrophils. snRNA analysis revealed that PTEN is mainly expressed in mesangial cells. Finally, RT-PCR results revealed that the mRNA expression of PTEN was upregulated in kidneys from db/db mice. Additionally, high-glucose treatment significantly upregulated PTEN expression in cultured human mesangial cells. This study identifies PTEN as a potential diagnostic biomarker for DN which may contribute to early detection and personalized therapeutic strategies.
- Open Access
- 23 December 2024
- Published byĀ Spandidos PublicationsĀ inĀ Molecular Medicine Reports
- Vol.Ā 31 Ā (3) , 1-20
Prospects for potential therapy targeting immuneāassociated factors in endometriosis (Review)
Endometriosis (EM) is a chronic inflammatory disease that is one of the most common causes of gynecological systemic lesions in women before menopause. The most representative histological feature of EM is that the endometrium appears outside of the uterine cavity, often in the ovary. Although it is generally accepted that the epithelial and stromal cells of the ectopic endometrium are not malignant, they still have numerous similarities to malignant tumors, including considerable changes to the immune microenvironment (immune monitoring disorder), the creation of a specific hormone environment, high levels of oxidative stress, chronic inflammation and abnormal immune cell regulation. The pathogenesis of EM is not fully understood, which makes it difficult to identify specific biomarkers and potential therapeutic targets for early disease diagnosis and effective treatment. However, considerable progress has been made in this field over the past few decades. The purpose of the present review is to summarize the confirmed and potential biomarkers for EM, and to identify potential therapeutic targets based on changes in immunological factors (including natural killer cells, macrophages, the complement system, miRNA and Pāselectin) in the ectopic endometrial tissue. It is hoped that this work can be used as the basis for identifying accurate diagnostic markers for EM and developing personalized immuneātargeted therapy.
- 23 December 2024
- Published byĀ Spandidos PublicationsĀ inĀ Molecular Medicine Reports
- Vol.Ā 31 Ā (3) , 1-20
Open AccessProspects for potential therapy targeting immuneāassociated factors in endometriosis (Review)
Endometriosis (EM) is a chronic inflammatory disease that is one of the most common causes of gynecological systemic lesions in women before menopause. The most representative histological feature of EM is that the endometrium appears outside of the uterine cavity, often in the ovary. Although it is generally accepted that the epithelial and stromal cells of the ectopic endometrium are not malignant, they still have numerous similarities to malignant tumors, including considerable changes to the immune microenvironment (immune monitoring disorder), the creation of a specific hormone environment, high levels of oxidative stress, chronic inflammation and abnormal immune cell regulation. The pathogenesis of EM is not fully understood, which makes it difficult to identify specific biomarkers and potential therapeutic targets for early disease diagnosis and effective treatment. However, considerable progress has been made in this field over the past few decades. The purpose of the present review is to summarize the confirmed and potential biomarkers for EM, and to identify potential therapeutic targets based on changes in immunological factors (including natural killer cells, macrophages, the complement system, miRNA and Pāselectin) in the ectopic endometrial tissue. It is hoped that this work can be used as the basis for identifying accurate diagnostic markers for EM and developing personalized immuneātargeted therapy.
- Open Access
- 24 October 2023
- Published byĀ Springer NatureĀ inĀ Cell Death & Disease
- Vol.Ā 14 Ā (10) , 1-13
Sohlh2 promotes pulmonary fibrosis via repression of p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway
Disturbance in the redox balance of alveolar epithelial cells (AECs) was considered as a causal factor for pulmonary fibrosis. The regulatory mechanisms of redox hemostasis in the development of pulmonary fibrosis remain largely unknown. Using a type II AEC-specific Sohlh2 conditional knock-in (CKI) mouse model, we found that Sohlh2, a basic HLH transcription factor, accelerated age-related pulmonary fibrosis. High-fat diet (HFD) resulted in a tremendous increase in lung inflammation and fibrotic changes in the lung tissues of Sohlh2 CKI mice. Sohlh2 overexpression led to a significant rise of intracellular ROS and apoptosis in the lung, mouse primary AECIIs, and human A549 cells, which was attenuated by ROS inhibitor (NAC). Sohlh2 enhanced oxidative stress via repressing p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway. p62, a direct target of Sohlh2, mediated Sohlh2 effects on ROS generation and apoptosis in A549 cells. Hence, our findings elucidate a pivotal mechanism underlying oxidative stress-induced pulmonary fibrosis, providing a framework for aging-related disorder interventions.
- 24 October 2023
- Published byĀ Springer NatureĀ inĀ Cell Death & Disease
- Vol.Ā 14 Ā (10) , 1-13
Open AccessSohlh2 promotes pulmonary fibrosis via repression of p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway
Disturbance in the redox balance of alveolar epithelial cells (AECs) was considered as a causal factor for pulmonary fibrosis. The regulatory mechanisms of redox hemostasis in the development of pulmonary fibrosis remain largely unknown. Using a type II AEC-specific Sohlh2 conditional knock-in (CKI) mouse model, we found that Sohlh2, a basic HLH transcription factor, accelerated age-related pulmonary fibrosis. High-fat diet (HFD) resulted in a tremendous increase in lung inflammation and fibrotic changes in the lung tissues of Sohlh2 CKI mice. Sohlh2 overexpression led to a significant rise of intracellular ROS and apoptosis in the lung, mouse primary AECIIs, and human A549 cells, which was attenuated by ROS inhibitor (NAC). Sohlh2 enhanced oxidative stress via repressing p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway. p62, a direct target of Sohlh2, mediated Sohlh2 effects on ROS generation and apoptosis in A549 cells. Hence, our findings elucidate a pivotal mechanism underlying oxidative stress-induced pulmonary fibrosis, providing a framework for aging-related disorder interventions.
- Open Access
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Supplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- Open Access
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Data from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Colon cancer stem cells (CSC) are tumor-initiating cells that drive tumorigenesis and progression through self-renewal and various differentiation potency. Therefore, the identification of factors critical for colon CSC function is vital for the development of therapies. Sohlh2 belongs to the superfamily of bhlh transcription factors and serves as a tumor suppressor in several tumors. The role of Sohlh2 in CSCs remains unknown. Here we demonstrated that Sohlh2 was related to the inhibition of LncRNA-H19/miR-141/β-catenin signaling and led to the consequent suppression of colon CSC stemness and the promotion of colon CSC differentiation in vitro and in vivo. Moreover, Sohlh2 could directly bind to the promoter of LncRNA-H19 and repress its transcription activity. LncRNA-H19 mediated the effects of Sohlh2 on colon CSC stemness and differentiation. Clinically, we observed a significant inverse correlation between Sohlh2 and LncRNA-H19, β-catenin, Lgr5, CD133 expression levels, and positive correlation between Sohlh2 and MUC2, TFF2 expression in colon cancer tissues. Collectively, our findings suggest an important role of the Sohlh2/LncRNA-H19/miR-141/β-catenin pathway in regulating colon CSC stemness and differentiation, suggesting potential therapeutic targets for colon cancer.Implications:This study identifies that Sohlh2 directly manipulates LncRNA-H19 transcription and suppresses the β-catenin signaling pathway and the Sohlh2/LncRNA-H19/miR-141/β-catenin signaling pathway plays an essential role in the stemness of colon CSCs.
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Open AccessData from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Colon cancer stem cells (CSC) are tumor-initiating cells that drive tumorigenesis and progression through self-renewal and various differentiation potency. Therefore, the identification of factors critical for colon CSC function is vital for the development of therapies. Sohlh2 belongs to the superfamily of bhlh transcription factors and serves as a tumor suppressor in several tumors. The role of Sohlh2 in CSCs remains unknown. Here we demonstrated that Sohlh2 was related to the inhibition of LncRNA-H19/miR-141/β-catenin signaling and led to the consequent suppression of colon CSC stemness and the promotion of colon CSC differentiation in vitro and in vivo. Moreover, Sohlh2 could directly bind to the promoter of LncRNA-H19 and repress its transcription activity. LncRNA-H19 mediated the effects of Sohlh2 on colon CSC stemness and differentiation. Clinically, we observed a significant inverse correlation between Sohlh2 and LncRNA-H19, β-catenin, Lgr5, CD133 expression levels, and positive correlation between Sohlh2 and MUC2, TFF2 expression in colon cancer tissues. Collectively, our findings suggest an important role of the Sohlh2/LncRNA-H19/miR-141/β-catenin pathway in regulating colon CSC stemness and differentiation, suggesting potential therapeutic targets for colon cancer.Implications:This study identifies that Sohlh2 directly manipulates LncRNA-H19 transcription and suppresses the β-catenin signaling pathway and the Sohlh2/LncRNA-H19/miR-141/β-catenin signaling pathway plays an essential role in the stemness of colon CSCs.
- Open Access
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Supplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- 3 April 2023
- Published byĀ American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-3, Figures 1-3 from Sohlh2 Regulates the Stemness and Differentiation of Colon Cancer Stem Cells by Downregulating LncRNA-H19 Transcription
Supplementary Table S1: Primer sequence for qPCR Supplementary Table S2: LncRNAs regulated by Sohlh2 in colon cancer cells Supplementary Table S3: The correlation of Sohlh2 expression and clinical characteristics Supplementary Figure 1: The protein levels of Lgr5, CD133 were downregulated in Sohlh2-overexpressing CSC-derived xenografts, and the levels of TFF2 were upregulated. Supplementary Figure S2: Sohlh2 downregulated the expression of β-catenin in xenograft tumors. Supplementary Figure S3: Sohlh2 upregulated the expression of APC in HCT116 CSCs.
- Open Access
- 3 February 2023
- Published byĀ MDPI AGĀ inĀ International Journal of Molecular Sciences
- Vol.Ā 24 Ā (3) , 2961
A New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction
Sarcomas are a group of malignant tumors derived from mesenchymal tissues that display complex and variable pathological types. The impact of the immune properties of the tumor microenvironment (TME) on the prognosis, treatment, and management of sarcomas has attracted attention, requiring the exploration of sensitive and accurate signatures. In this study, The Cancer Genome Atlas (TCGA) database was searched to screen for an RNA sequencing dataset, retrieving 263 sarcoma and 2 normal samples with survival data. Genes associated with immune regulation in sarcomas were retrieved from the Tumor Immune Estimation Resource database to estimate tumor purity and immune cell infiltration levels. The samples were then divided into the immune-high and immune-low groups. Then, we screened for differentially expressed genes (DEGs) between the two groups. The intersection between immune-related genes and DEGs was then determined. Univariate Cox and least absolute shrinkage and selection operator analyses were used to select ideal genes for prognostic prediction and subsequent construction of a risk signature. A survival analysis was performed to reveal the dissimilarity in survival between the high- and low-score groups. Finally, a nomogram was generated to verify the accuracy and reliability of the signature. Through Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression (ESTIMATE) analysis, high ESTIMATE, and low tumor purity were significantly associated with a favorable prognosis. Moreover, a total of 5259 DEGs were retrieved, the majority of which were downregulated. In total, 590 immune-associated genes overlapped with the DEGs, among which nine hub genes were identified. Finally, two candidate genes, ACVR2B and NFYA, were identified, based on which a risk signature was constructed. The risk signature constructed in this study is accurate and reliable for the prognostic prediction and phenotyping of sarcomas.
- 3 February 2023
- Published byĀ MDPI AGĀ inĀ International Journal of Molecular Sciences
- Vol.Ā 24 Ā (3) , 2961
Open AccessA New Signature of Sarcoma Based on the Tumor Microenvironment Benefits Prognostic Prediction
Sarcomas are a group of malignant tumors derived from mesenchymal tissues that display complex and variable pathological types. The impact of the immune properties of the tumor microenvironment (TME) on the prognosis, treatment, and management of sarcomas has attracted attention, requiring the exploration of sensitive and accurate signatures. In this study, The Cancer Genome Atlas (TCGA) database was searched to screen for an RNA sequencing dataset, retrieving 263 sarcoma and 2 normal samples with survival data. Genes associated with immune regulation in sarcomas were retrieved from the Tumor Immune Estimation Resource database to estimate tumor purity and immune cell infiltration levels. The samples were then divided into the immune-high and immune-low groups. Then, we screened for differentially expressed genes (DEGs) between the two groups. The intersection between immune-related genes and DEGs was then determined. Univariate Cox and least absolute shrinkage and selection operator analyses were used to select ideal genes for prognostic prediction and subsequent construction of a risk signature. A survival analysis was performed to reveal the dissimilarity in survival between the high- and low-score groups. Finally, a nomogram was generated to verify the accuracy and reliability of the signature. Through Estimation of STromal and Immune cells in MAlignant Tumour tissues using Expression (ESTIMATE) analysis, high ESTIMATE, and low tumor purity were significantly associated with a favorable prognosis. Moreover, a total of 5259 DEGs were retrieved, the majority of which were downregulated. In total, 590 immune-associated genes overlapped with the DEGs, among which nine hub genes were identified. Finally, two candidate genes, ACVR2B and NFYA, were identified, based on which a risk signature was constructed. The risk signature constructed in this study is accurate and reliable for the prognostic prediction and phenotyping of sarcomas.